Optometrists and ophthalmologists are finding success treating dry eye disease using weak alternate electrical current patterns.
Rexon-Eye developed by Resono Ophthalmic and distributed in Australia and New Zealand by Eyetek, sends electrical signals to stimulate the metabolism and natural regeneration of malfunctioning cells and tissues, such as the lacrimal glands and meibomian glands.
Our bodies rely on electrical currents to function – they stimulate our muscles to contract and we see or hear because our eyes and ears generate and transmit electrical signals to our brain. Electrical currents – both naturally and artificially generated – can also affect the body’s repair and healing processes.
Research conducted at Telea Electronic Engineering led to the discovery of Quantum Molecular Resonance (QMR), which emits an alternating electrical signal containing a specific range of frequencies, from four to 16 MHz, that are the same as the molecular bonds in biological tissue.
Subsequent experiments found widening the range of frequencies, from four to 64 MHz, stimulated the metabolism and natural regeneration of biological tissue and cells.
The Rexon-Eye device uses a QMR generator and a mask electrode to optimally apply treatment to the ocular and peri-ocular area. Granted a CE mark in 2016 as a ‘Medical device for the treatment of ocular surface disorders’, it entered the ophthalmic market in 2018 as a therapeutic device.
Future applications for Rexon- Eye include healing following cataract, refractive, corneal graft and transplant surgery. Clinical studies are underway.
